{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:06:47Z","timestamp":1779898007399,"version":"3.53.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1028543"],"award-info":[{"award-number":["1028543"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","award":["100411"],"award-info":[{"award-number":["100411"]}],"id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pregnancy Hypertension"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.preghy.2018.09.010","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T02:32:22Z","timestamp":1538533942000},"page":"156-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Maternal and perinatal outcomes associated with the use of renin-angiotensin system (RAS) blockers for chronic hypertension in early pregnancy"],"prefix":"10.1016","volume":"14","author":[{"given":"Bilal","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duong T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Zoega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa R.","family":"Jorm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alys","family":"Havard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.preghy.2018.09.010_b0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","article-title":"Clinical practice guidelines for the management of hypertension in the community","volume":"16","author":"Weber","year":"2014","journal-title":"J. Clin. Hypertens."},{"issue":"5 SUPPL 1","key":"10.1016\/j.preghy.2018.09.010_b0010","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","author":"Levey","year":"2004","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.preghy.2018.09.010_b0015","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/HJH.0000000000000069","article-title":"Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations","volume":"32","author":"Al Khaja","year":"2014","journal-title":"J. Hypertens."},{"issue":"4","key":"10.1016\/j.preghy.2018.09.010_b0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/HYPERTENSIONAHA.112.197095","article-title":"Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population","volume":"60","author":"Bateman","year":"2012","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.preghy.2018.09.010_b0025","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/AOG.0000000000001775","article-title":"Angiotensin-converting enzyme inhibitors and the risk of congenital malformations","volume":"129","author":"Bateman","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.preghy.2018.09.010_b0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5931","article-title":"Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study","volume":"343","author":"Li","year":"2011","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.preghy.2018.09.010_b0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00228-009-0620-0","article-title":"Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants","volume":"65","author":"Lennest\u00e5l","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"129","key":"10.1016\/j.preghy.2018.09.010_b0040","article-title":"The use of angiotensin converting enzyme inhibitors during the first trimester of pregnancy","volume":"2","author":"Lyn Colvin","year":"2014","journal-title":"J. Pharmacovigilance"},{"issue":"2","key":"10.1016\/j.preghy.2018.09.010_b0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.112.196352","article-title":"Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists A systematic review","volume":"60","author":"Bullo","year":"2012","journal-title":"Hypertension"},{"issue":"7628","key":"10.1016\/j.preghy.2018.09.010_b0050","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/bmj.39363.706956.55","article-title":"Maternal and neonatal individual risks and benefits associated with caesarean delivery: multicentre prospective study","volume":"335","author":"Villar","year":"2007","journal-title":"Br. Med. J."},{"key":"10.1016\/j.preghy.2018.09.010_b0055","first-page":"1","article-title":"Pregnancy outcome after first trimester use of angiotensin AT1 receptor blockers: an observational cohort study","author":"Hoeltzenbein","year":"2018","journal-title":"Clin. Res. Cardiol."},{"issue":"4","key":"10.1016\/j.preghy.2018.09.010_b0060","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/HYPERTENSIONAHA.107.107565","article-title":"Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study","volume":"51","author":"Chappell","year":"2008","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.preghy.2018.09.010_b0065","article-title":"The Smoking MUMS (Maternal Use of Medications and Safety) Study: protocol for a population-based cohort study using linked administrative data","volume":"3","author":"Havard","year":"2013","journal-title":"Br. Med. J. Open"},{"key":"10.1016\/j.preghy.2018.09.010_b0070","series-title":"New South Wales Mothers and Babies 2014","author":"Centre for Epidemiology and Evidence","year":"2016"},{"key":"10.1016\/j.preghy.2018.09.010_b0075","series-title":"The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM)-Fifth Edition-Tabular List of Diseases and Alphabetic Index of Diseases","author":"National Centre for Classification in Health","year":"2006"},{"key":"10.1016\/j.preghy.2018.09.010_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d6667","article-title":"Fetal risk from ACE inhibitors in the first trimester","volume":"343","author":"Mitchell","year":"2011","journal-title":"Br. Med. J."},{"issue":"3","key":"10.1016\/j.preghy.2018.09.010_b0085","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/10641950701826695","article-title":"The accuracy of reporting of the hypertensive disorders of pregnancy in population health data","volume":"27","author":"Roberts","year":"2008","journal-title":"Hypertens. Pregnancy"},{"key":"10.1016\/j.preghy.2018.09.010_b0090","first-page":"11(1)","article-title":"Use of hospitalisation history (lookback) to determine prevalence of chronic diseases: impact on modelling of risk factors for haemorrhage in pregnancy","author":"Chen","year":"2011","journal-title":"BioMed Central Med. Res. Methodol."},{"issue":"1","key":"10.1016\/j.preghy.2018.09.010_b0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.diabres.2008.03.001","article-title":"The accuracy of population health data for monitoring trends and outcomes among women with diabetes in pregnancy","volume":"81","author":"Bell","year":"2008","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.preghy.2018.09.010_b0100","doi-asserted-by":"crossref","unstructured":"NSW Health Department, Validation Study: NSW Midwives Data Collection 1998. 1998 2000:9(S-2):97-9. New South Wales Mothers and Babies, 2000 9 97\u20139.","DOI":"10.1071\/NB00045"},{"key":"10.1016\/j.preghy.2018.09.010_b0105","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2013. Oslo, 2012."},{"key":"10.1016\/j.preghy.2018.09.010_b0110","series-title":"Pharmacoepidemiology and Drug Safety","article-title":"Pregnancy outcomes in women with chronic hypertension initiated on labetalol versus methyldopa","author":"Bateman","year":"2016"},{"issue":"5","key":"10.1016\/j.preghy.2018.09.010_b0115","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5694\/mja11.11331","article-title":"Australian national birthweight percentiles by sex and gestational age, 1998\u20132007","volume":"197","author":"Dobbins","year":"2012","journal-title":"Med. J. Aust."},{"issue":"4","key":"10.1016\/j.preghy.2018.09.010_b0120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ajog.2012.11.011","article-title":"Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes","volume":"208","author":"Orbach","year":"2013","journal-title":"Am. J. Obstetetr. Gynecol."},{"key":"10.1016\/j.preghy.2018.09.010_b0125","unstructured":"Australian Bureau of Statistics, 2033.0.55.001. Census of population and housing: Socio-Economic Indexes for Areas (SEIFA), Australia 2006. 2008 Available from: <www.abs.gov.au\/AUSSTATS\/abs@.nsf\/Lookup\/2033.0.55.001Main\u00b1Features12006?OpenDocument\/>."},{"key":"10.1016\/j.preghy.2018.09.010_b0130","unstructured":"Australian Bureau of Statistics, Australian standard geographical classification (ASGC). Canberra. <http:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/0\/0D204FD3DCD90564CA256F19001303A2?opendocument\/>, 2005 (accessed 7 December 2016)."},{"issue":"3","key":"10.1016\/j.preghy.2018.09.010_b0135","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/1753-6405.12213","article-title":"Linking birth records to hospital admission records enhances the identification of women who smoke during pregnancy","volume":"38","author":"Tran","year":"2014","journal-title":"Aust. N. Z. J. Public Health"},{"key":"10.1016\/j.preghy.2018.09.010_b0140","unstructured":"Epi Info [computer program] Version 6. Atlanta: Centers for Disease control and prevention 1994."},{"issue":"1","key":"10.1016\/j.preghy.2018.09.010_b0145","first-page":"9","article-title":"Antihypertensive drug therapy for mild to moderate hypertension during pregnancy","volume":"147","author":"Abalos","year":"2007","journal-title":"Rev. Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.preghy.2018.09.010_b0150","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/1471-0528.12678","article-title":"Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy","volume":"121","author":"Xie","year":"2014","journal-title":"BJOG: Int. J. Obstetr. Gynaecol."},{"issue":"2","key":"10.1016\/j.preghy.2018.09.010_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053844","article-title":"Pregnancy outcomes of anti-hypertensives for women with chronic hypertension: a population-based study","volume":"8","author":"Su","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.preghy.2018.09.010_b0160","unstructured":"SAS Institute Inc. Statistical Analysis Software [Online]. <www.sas.com\/>, 2012 (accessed 20 December 2017)."},{"key":"10.1016\/j.preghy.2018.09.010_b0165","series-title":"IBM SPSS Statistics 22. Algorithms","author":"SPSS","year":"2013"},{"issue":"4","key":"10.1016\/j.preghy.2018.09.010_b0170","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.reprotox.2011.02.008","article-title":"Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers","volume":"31","author":"Diav-Citrin","year":"2011","journal-title":"Reprod. Toxicol."},{"issue":"1","key":"10.1016\/j.preghy.2018.09.010_b0175","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/pds.3284","article-title":"Algorithms to estimate the beginning of pregnancy in administrative databases","volume":"22","author":"Margulis","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"9","key":"10.1016\/j.preghy.2018.09.010_b0180","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/pds.3472","article-title":"Challenges of using primary care electronic medical records in the UK to study medications in pregnancy","volume":"22","author":"Cea-Soriano","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["Pregnancy Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210778918300667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210778918300667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:22:21Z","timestamp":1779895341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210778918300667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":36,"alternative-id":["S2210778918300667"],"URL":"https:\/\/doi.org\/10.1016\/j.preghy.2018.09.010","relation":{},"ISSN":["2210-7789"],"issn-type":[{"value":"2210-7789","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maternal and perinatal outcomes associated with the use of renin-angiotensin system (RAS) blockers for chronic hypertension in early pregnancy","name":"articletitle","label":"Article Title"},{"value":"Pregnancy Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.preghy.2018.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}